Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Rhea-AI Summary
Rigel Pharmaceuticals (Nasdaq: RIGL) will report first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Senior management will host a live conference call and webcast at 4:30 p.m. ET to discuss results and business updates.
Dial-in numbers are 877-407-3088 (domestic) and 201-389-0927 (international). The webcast, slides, and a replay will be available from the Investor Relations section of www.rigel.com and archived for 90 days.
Rigel is a biotechnology company focused on therapies for hematologic disorders and cancer, based in South San Francisco.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – RIGL
On the day this news was published, RIGL gained 0.16%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Within Biotechnology peers, price changes span from -0.18% (NRIX) to 11.19% (ANAB), while RIGL’s pre-news move was 0.73%, suggesting stock-specific dynamics rather than a coordinated sector move.
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings call scheduling | Neutral | +0.7% | Announced timing and access details for Q4 and full-year 2025 results call. |
Prior earnings-date conference call announcements produced a small, muted price reaction of 0.73%, indicating these scheduling releases have had limited impact on the stock.
Over recent months Rigel has balanced operational progress with routine investor communications. A prior earnings-date conference call notice on Feb 24, 2026 led to a mild 0.73% move. Around that period, the company also reported strong 2025 financials, advanced its hematology/oncology pipeline, and added a new board member. Today’s announcement fits the pattern of providing logistical details ahead of quarterly results rather than introducing new financial or clinical data.
Historical Comparison
In the past, Rigel’s earnings-date conference call notices led to a modest 0.73% move, suggesting such scheduling updates typically have limited standalone trading impact.
Rigel consistently pre-announces conference calls around quarterly results, maintaining a regular cadence of earnings-date communications without adding new financial metrics in these notices.
Market Pulse Summary
This announcement schedules the release of Rigel’s first quarter 2026 results for May 5, 2026 and provides access details for the conference call and webcast. It does not include new financial or clinical data. Historically, similar earnings-date notices produced only modest stock moves. Investors may focus next on the actual Q1 figures, commentary on the hematology/oncology portfolio, and any updates following recent regulatory and partnership developments.
AI-generated analysis. Not financial advice.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-first-quarter-2026-financial-results-302754902.html
SOURCE Rigel Pharmaceuticals, Inc.